Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good evening and welcome to DIATIC's International Full Year 2025 Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief question and answer session. As a reminder, this conference call is being recorded today, March 25, 2026. I would now like to turn the call over to Mrs. Ping Rawson, DIATIC's Chief Financial Officer. Please go ahead. Thank you, operator. Good evening and welcome everyone to Dyadic's full year 2025 conference call. I hope you have had the opportunity to review Dyadic's press releases announcing financial results for the year ended December 31st, 2025. You may access our release and form 10K and the investor section of the company's website at dyadic.com. On today's call, Our President and Chief Operating Officer, Joe Hazelton, will review our full year 2025 business and corporate highlights and provide a commentary on the strategic direction of the business. Our CEO, Mark Emelfarb, will provide an update on our biopharmaceutical programs, and I will follow with a review of our financial results in more detail, after which we'll hold a brief Q&A session. At this time, I would like to inform you that certain commentary made in this conference call may be considered forward-looking statements, which involve risks and uncertainties and other factors that could cause DADEC's actual results, performance, scientific or otherwise, or achievements to be materially different from those expressed or implied by these forward-looking statements. DADEC expressly disclaims any duty to provide updates to its forward-looking statements, whether because of new information, future events, or otherwise. Participants are directed to the risk factors set forth in dyadic reports filed with the...